Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL
NCT03447808Phase 1Completed
- Start
- Aug 2018
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab and ibrutinib in chronic lymphocytic leukemia (CLL). Primary endpoints: Complete response (CR) + complete response with incomplete marrow recovery (CRi) up to 2 years and Incidence of adverse events up to 2 years. Started Aug 2018; status: completed.
02
Drugs
daratumumabibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03447808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03447808.